Scinai Immunotherapeutics
SCNI
10 hedge funds and large institutions have $2.13M invested in Scinai Immunotherapeutics in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
9% less funds holding
Funds holding: 11 → 10 (-1)
15% less capital invested
Capital invested by funds: $2.51M → $2.13M (-$384K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mariner
Overland Park,
Kansas
|
+$146K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$15K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$8.63K |
| 3 |
BHB
Bank Hapoalim BM
Tel Aviv,
Israel
|
-$1.62K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
II
1
Ibex Investors
Denver,
Colorado
| $1.71M | – | – | – |
|
|
2
Mariner
Overland Park,
Kansas
| $129K | +$146K | +270 | New |
|
|
BHB
3
Bank Hapoalim BM
Tel Aviv,
Israel
| $119K | -$1.62K | -3 | -1% |
|
4
HighTower Advisors
Chicago,
Illinois
| $81K | – | – | – |
|
|
PVH
5
Psagot Value Holdings
Tel Aviv,
Israel
| $52K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $14K | -$8.63K | -16 | -35% |
|
|
LTFS
7
Ladenburg Thalmann Financial Services
Miami,
Florida
| $12K | – | – | – |
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | – | – | – |
|
9
Wells Fargo
San Francisco,
California
| $4K | – | – | – |
|
10
Morgan Stanley
New York
| $2K | – | – | – |
|
|
11
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$15K | -26 | Closed |
|
SCNI Hedge Fund Activity: Q4 2018 in Review
10 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2018, worth a combined $2.13M — down 15% from $2.51M a quarter earlier.
Fund positioning in SCNI was balanced in Q4 2018: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 2 trimmed.
The largest buyer was Mariner, opening a new position worth an estimated $146K. The largest seller was Deutsche Bank, exiting entirely with an estimated $15K sold.
- 10 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2018, down from 11 in Q3 2018.
- Funds reported $2.13M of Scinai Immunotherapeutics stock for Q4 2018, down 15% quarter-over-quarter.
- 1 fund opened new Scinai Immunotherapeutics positions in Q4 2018 and 1 closed out, a net change of 0 holders.
- The largest Scinai Immunotherapeutics buyer in Q4 2018 was Mariner, an estimated $146K added.
- The largest Scinai Immunotherapeutics seller in Q4 2018 was Deutsche Bank, an estimated $15K sold.
Based on aggregated 13F filings for Q4 2018.